XTX Topco Ltd Purchases 20,720 Shares of uniQure N.V. (NASDAQ:QURE)

Key Points

• XTX Topco Ltd increased its investment in uniQure N.V. by 127.3% in Q1, resulting in a position valued at $392,000. This marks a notable rise in hedge fund and institutional ownership of the stock.
• Wall Street analysts' ratings on uniQure are predominantly positive, with four analystssix as "buy," and two as "strong buy," alongside various target prices ranging from $28.00 to $70.00.
• uniQure recently reported an earnings loss of ($0.69) EPS, surpassing analysts' expectations, while its revenue for the quarter was $5.26 million, also exceeding estimates.

XTX Topco Ltd grew its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 127.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,999 shares of the biotechnology company's stock after purchasing an additional 20,720 shares during the quarter. XTX Topco Ltd owned approximately 0.07% of uniQure worth $392,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Tudor Investment Corp ET AL boosted its position in shares of uniQure by 5.9% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after acquiring an additional 1,371 shares during the period. Wells Fargo & Company MN boosted its position in shares of uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after acquiring an additional 1,503 shares during the period. Northern Trust Corp boosted its position in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after acquiring an additional 1,923 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock valued at $1,253,000 after acquiring an additional 3,996 shares during the period. Finally, Mraz Amerine & Associates Inc. bought a new position in shares of uniQure in the first quarter worth $106,000. 78.83% of the stock is owned by institutional investors.

Insider Transactions at uniQure

In other uniQure news, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the sale, the director directly owned 34,190 shares of the company's stock, valued at approximately $494,045.50. The trade was a 5.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Madhavan Balachandran sold 2,112 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director directly owned 37,697 shares in the company, valued at $544,721.65. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is owned by insiders.

uniQure Trading Up 2.9%

NASDAQ:QURE traded up $0.42 during trading hours on Wednesday, hitting $14.72. 200,552 shares of the company were exchanged, compared to its average volume of 1,391,800. The stock has a market capitalization of $807.69 million, a price-to-earnings ratio of -3.76 and a beta of 0.11. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure N.V. has a one year low of $4.45 and a one year high of $19.18. The company has a fifty day simple moving average of $14.67 and a 200 day simple moving average of $13.63.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The business had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. Sell-side analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on QURE shares. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Cantor Fitzgerald set a $47.00 price target on uniQure in a research report on Wednesday, July 30th. Chardan Capital reduced their price objective on uniQure from $38.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, July 29th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.55.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.